Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Dacomitinib (Primary) ; Figitumumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Oct 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 24 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 04 May 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.